Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical and Molecular Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response or Facial Erythema After Treatment With Dupilumab

NCT05602207 is registered in ClinicalTrials.gov with Innovaderm Research Inc. as lead sponsor.

NCT NCT05602207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05602207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical and Molecular Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response or Facial Erythema After Treatment With Dupilumab
Lead sponsor
Innovaderm Research Inc.
Phase
Phase 4
Overall status
Completed
Start date
November 25, 2022
Completion date
January 9, 2025
Enrollment
24 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis